BMS309403 is orally active, reducing atherosclerosis in mice lacking apoplipoprotein E.

(S)-SBFI-26 is the (S) enantiomer of SBFI-26, an anti-nociceptive agent binds to anandamide transporters FABP5 and FABP7. (S)-SBFI-26 has anti-nociceptive and anti-inflammatory effects.

FABP5-IN-1(Compounds 4j) is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a Ki value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effects.

FABP-IN-1 (Compounds 4b) is a high affinity fatty acid binding protein (FABP) inhibitor. FABP-IN-1 inhibits FABP3, FABP5, and FABP7 with Ki values of 0.69 μM, 0.55 μM and 0.67 μM, respectively. FABP-IN-1 displays potent antinociceptive effects.

BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (aFABP, aP2) with a Ki of <2 nM, 250, and 350 nM for aFABP, muscle FABP (mFABP), and epidermal FABP (eFABP), respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells.

FABPs ligand 6 (MF6) is an FABP5 and FABP7 inhibitor with KD values of 874 nM and 20 nM, respectively. FABPs ligand 6 can be used for multiple sclerosis research.